Owain Powell-Jones

When India accidentally wiped out its vultures, half a million people died in five years. The bird doing zoomies in this video runs the most extreme digestive system in the animal kingdom. Vulture stomach acid sits near pH 1, strong enough to destroy anthrax, rabies, and botulism in the carcasses they eat. A flock strips a cow to bone in about 45 minutes. India had 50 million of them. Free sanitation at national scale, in a country where religious custom means most cattle die natural deaths and every dead cow becomes a carcass someone has to deal with. Then the patent on diclofenac expired in 1994. Farmers started using the cheap painkiller on livestock. Trace amounts left in a carcass cause kidney failure in vultures. Within a decade, 50 million birds fell to a few thousand. The fastest collapse of any bird species since the passenger pigeon. The carcasses didn't disappear. Feral dogs took the vultures' place and brought rabies with them. Rotting remains leached into waterways. In districts where vultures once thrived, human death rates rose more than 4 percent. Economists at Chicago and Warwick put the toll at 100,000 extra deaths a year and $69 billion in annual damages. So yes, the goofy bird sprinting down the walkway is adorable. It's also a disease firewall that evolution spent millions of years building and one generic painkiller nearly erased in ten.

A dog's nose has around 300 million scent receptors. Yours has about 6 million. In a 1,502-person trial in Bangalore, trained dogs detected early-stage cancer from breath samples with roughly 90% sensitivity. Then they did something nobody trained them to do. Tumors rewire cell metabolism, and that altered metabolism leaks volatile organic compounds into your blood, which diffuse into your lungs and exit in your breath. The concentrations are parts per trillion. Roughly one drop of scent in 20 Olympic pools. No commercial breath machine reads reliably at that level. A dog does it in seconds. Dogs have flagged disease in over 50 peer-reviewed studies across 28 conditions. The reason none of it ever reached a clinic is that a dog isn't a repeatable instrument. Two handlers read the same sniff differently. So the startup, Dognosis, strapped sensors to the dogs, tracking movement, respiration, and brain activity, and trained an AI to translate the animal into standardized clinical output. The AI doesn't smell anything. It reads the dog. Then the part that should make researchers sit up. Dogs trained on 10 cancer types correctly flagged an 11th type they had never been shown. They generalized. That implies cancer may have a shared chemical signature across tumor types, one no lab has isolated, that a beagle named Whiskey can pick out of a breath mask. The Phase 2 results were published in the Journal of Clinical Oncology, though the headline figures are still company-reported. A 10,000-person Phase 3 trial is now underway. The at-home version targets a 2027 launch in India at a few thousand rupees per test, breathe into a mask for 10 minutes, courier it to a farm outside Bangalore, and a dog clocks in for its shift. We sequenced the human genome for $300. The most sensitive cancer detector on the planet still works for kibble.